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ABSTRACT
Purpose. This study was designed to assess the diagnostic
accuracy and therapeutic efficacy of probe-based confocal
laser endomicroscopy (pCLE), which provides real-time,
in vivo histological information during transurethral
resection of bladder tumors.
Methods. We performed a prospective study between
August 2013 and August 2014. pCLE was performed on a
total of 119 lesions in 75 patients. We analyzed the diag-
nostic accuracy of pCLE by comparing the confocal image
reports with the pathology reports of surgical specimen.
Confocal images were interpreted by a single urologist
blinded to the pathology reports. The therapeutic efficacy
was analyzed by comparing the outcomes in pCLE and
non-pCLE groups.
Results. In a total of 119 lesions, 23 were benign and 96
were malignant. The detection accuracy for malignant
lesions with pCLE was determined with a sensitivity and a
positive predictive value (PPV) of 91.7% and 93.6%,
respectively. For high-grade versus low-grade bladder
cancer, sensitivity and PPV of pCLE were 94.5% and
89.7%, respectively. Distinguishing carcinoma in situ from
inflammatory lesions also was accurate with sensitivity,
specificity, and PPV of 71.4%, 81.3%, and 83.3%,
respectively. The Kaplan–Meier curves revealed that the
recurrence-free survival rate was significantly higher in the
pCLE group than in the non-pCLE group (p = 0.031).
Conclusions. Probe-based confocal laser endomicroscopy
is a promising method to provide the surgeon during the
transurethral resection of a bladder tumor with real-time
tumor histology, regardless of the tumor’s gross appear-
ance. Furthermore, it also may improve the therapeutic
efficacy with longer recurrence-free periods.
Bladder cancer is one of the most common malignant
tumors in the urinary tract.1 For newly diagnosed tumors,
approximately 75% are nonmuscle-invasive bladder can-
cers (NMIBC), which have a high risk of recurrence, but a
good survival rate.2 Recurrence and progression are more
frequent in high-grade tumors.3–5 Hence, identification of
high-grade tumors is crucial for the management of bladder
cancer.
Although there is a clear consensus that carcinoma
in situ (CIS) contribute to greater mortality and morbidity,
there still are no favorable imaging techniques for their
detection. In current everyday practice, the detection of
CIS only depends on the findings from white-light cys-
toscopy (WLC) and biopsies. Although the biopsy is an
accurate and widely accepted method for assessment, it
may be unnecessary for treatment selection and carries the
risk of complications. However, during an inspection of the
bladder under WLC alone, the margin of a CIS is
ambiguous, which interferes with the complete endoscopic
tumor resection or may result in excessive cauterization of
the bladder mucosa, possibly leading to voiding
difficulties.
Recently, efforts for the development of optical imaging
technologies were made to overcome the limitations of
conventional WLC. The newly introduced narrow-band
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imaging (NBI) and blue-light cystoscopy (BLC) also are
based on gross images only. However, probe-based con-
focal laser endomicroscopy (pCLE), based on histological
findings and providing real-time histopathological infor-
mation to the surgeon, is a more promising technique for
both diagnostic and therapeutic purposes. Confocal laser
endomicroscopy (CLE) was first introduced in 2004, and
its usage has initially been expanded into the treatment of
gastrointestinal and, later, biliopancreatic diseases. Nowa-
days, CLE is used in various specialties, such as
pulmonology, dermatology, and urology.6–10
The pCLE system uses a semiflexible probe, which can
be advanced to the bladder through the working channel of
the cystoscope. The pCLE image is obtained by focusing
low-energy laser light on a specific tissue layer that will
emit fluorescent light, which is recorded by a photodetector
and transformed into a gray-scale image that represents the
specific tissue layer. The pCLE can provide a real-time
intraoperative diagnosis of the tumor grade without the
need for frozen biopsies.11,12
We hypothesized that structural differences of abnormal
lesions in pCLE findings are highly correlated with
abnormal histopathological findings in bladder lesions.
Because of this reason, we also hypothesized that more
precise TURB can be performed according to each pCLE
findings which will maximize the therapeutic efficacy. To
our knowledge, until now there were no prospective studies
that assessed the diagnostic accuracy of pCLE in bladder
cancer with only one study evaluating pCLE as a diag-
nostic tool. Therefore, we performed a prospective study to
assess the diagnostic accuracy and therapeutic efficacy of
pCLE for bladder cancer.
MATERIALS AND METHODS
Patients
Between August 2013 and August 2014, pCLEs were
performed on a total of 119 lesions in 75 patients. All
patients who were planned for transurethral resection of
bladder tumor (TUR-BT) were included in the pCLE
group. Patients were excluded and placed into the non-
pCLE group under the following conditions: inability to
receive informed consent; fluorescein allergy; serum crea-
tinine above the upper limit; pregnancy or breastfeeding;
uncorrected coagulopathy; and severe thrombocytopenia.
All patients provided written, informed consent before
enrollment into the current study, which was approved by
the Yonsei University Hospital Institutional Review Board
(1-2010-0013).
Probe-Based CLE
TUR-BT and pCLE image acquisitions were performed
under spinal or general anesthesia and were completed by a
single surgeon (YDC). Initially, we characterized the
location, shape, and size of a lesion with conventional
WLC. Before pCLE scanning, 300–400 mL of normal
saline with 0.1% fluorescein (Novartis, Lake Forest, IL)
was filled into the bladder cavity for tissue contrast. Five
minutes after the fluorescein injection, pCLE images were
obtained using a 2.5-mm diameter probe (UHD GastroFlex,
CellVizio; Mauna Kea Technologies, Paris, France). This
probe has a resolution of 1 lm, a field of view of 240 lm,
and a 10009 magnification with 12 frames/s. To obtain
diagnostic images, the probe was placed on the target
lesion and scanned with pCLE. The mucosal tissue sur-
rounding the target lesion also was scanned. After
obtaining the images, monopolar TUR-BT was performed.
The resected specimens were sent to the same pathologist
at the same institution for histological review.
Diagnostic Outcome Measures
Postoperatively, pCLE images were reviewed and clas-
sified into six categories (inflammation, papilloma,
papillary urothelial neoplasm of low malignant potential
[PUNLMP], low-grade tumor, high-grade tumor, and car-
cinoma in situ) by a single urologist who has been educated
for classifying pCLE images. This reviewer was blinded to
the medical histories and histological diagnoses of the
patients. The histological diagnosis of each patient was
used as a reference to assess the diagnostic accuracy of
pCLE images through sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV). To compare the diagnoses from the pCLE images
with those from the histopathology report, we analyzed the
2 9 2 crosstab transformations malignant versus benign
lesions, high-grade versus low-grade tumors, and CIS
versus inflammation.
Evaluation of the Therapeutic Effects of pCLE
The therapeutic efficacy of pCLE was evaluated only
among patients who had T1 high-grade urothelial carci-
noma. All information was obtained prospectively, and
comparisons were made between pCLE and non-pCLE
groups. We resected all masses and cauterized any grossly
suspicious area. All patients with a pathologic diagnosis of
T1 high-grade urothelial carcinoma received six courses of
adjuvant intravesical bacillus Calmette-Gue´rin therapy.
Follow-up cystoscopy and cytology were done in regular
intervals of 3 months for 2 years and additionally at times
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of gross hematuria events. Recurrence was defined as a
cystoscopic and pathologic tumor detection.
Statistical Analysis
Qualitative data are presented as frequencies or per-
centages; continuous data are provided as means and
standard deviation without comparing each group. Sensi-
tivity, specificity, PPV, and NPV with 95% confidence
intervals were calculated with Medcalc (version 18.3.;
Mariakerke, Belgium). The Kaplan–Meier curve was
extracted by SPSS version 23 (SPSS Inc., Chicago, IL).
Associations were considered statistically significant for
two-sided p\ 0.05.
RESULTS
Patient demographics and lesion characteristics are
summarized in Table 1. A total of 75 patients were eligible
to be enrolled in the study, which included 119 lesions.
Male to female ratio was 6.5:1 with a total mean age of
68.32 ± 9.45 years. Histopathological results established
that 23 (19.3%) of the lesions were benign (papilloma, 4;
inflammation, 16; low malignant potential, 3) and 96
(80.7%) of the lesions were malignant (low-grade urothe-
lial carcinoma, 20; high-grade urothelial carcinoma, 55;
carcinoma in situ, 21). Based on gross appearance, 78
lesions were papillary (65.5%) and 41 lesions were flat
(34.5%). The pCLE was performed successfully without
any adverse effects in all pCLE group patients. Also, there
were no systemic toxicity, allergic, or hypersensitive
reactions with intravesical fluorescein administration.
pCLE Image Outcomes
The pCLE was performed on the normal mucosa of the
bladder for all patients in the pCLE group. Normal bladder
mucosa of pCLE yielded images of large umbrella cells
and uniform intermediate cells on the surface. A lamina
propria with its vascular network and scarce cellular con-
nective tissue also were identified. On the resection bed
after TUR-BT, the fat tissue and muscularis propria were
occasionally visualized by pCLE (Fig. 1). Using only
pCLE, it was difficult to differentiate between papilloma
and PUNLMP. Both lesions showed thin, papillary,
fibrovascular stalks and no other significant differences in
cell size and shape. However, in most cases, confocal
images revealed definite differences between normal
TABLE 1 Patient demographics and lesion characteristics
Demographic Total Lesions
Benign Malignant
Inflammation Papilloma Low malignant potential Low grade High grade CIS
Lesions, no. 119 16 4 3 20 55 21
Sex, no.
Male 90 9 3 2 16 44 16
Female 29 7 1 1 4 11 5
Age 68.32 67.55 68.00 44.00 68.00 69.89 67.64
(mean ± SD) ± 9.45 ± 7.41 ± 15.56 ± 5.20 ± 8.08 ± 9.39 ± 10.49
Histopathological TNM staging
T0 23 16 4 3 0 0 0
Ta 37 0 0 0 20 17 0
Tis 21 0 0 0 0 0 21
T1 28 0 0 0 0 28 0
T2a 9 0 0 0 0 9 0
T2b 0 0 0 0 0 0 0
T3a 1 0 0 0 0 1 0
T3b 0 0 0 0 0 0 0
T4 0 0 0 0 0 0 0
Shape
Nonpapillary 41 16 0 0 0 4 21
Papillary 78 0 4 3 20 51 0
CIS carcinoma in situ, SD standard deviation
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mucosa, low-, and high-grade urothelial carcinoma. In low-
grade carcinoma, branched-papillary fibrovascular stalks
and densely packed monomorphic urothelial cells were
noted. Some of these confocal diagnostic criteria showed
an overlap between high- and low-grade urothelial carci-
noma, such as the presence of fibrovascular stalks or
densely packed cells. High-grade urothelial carcinoma,
however, exhibited more loss of cellular cohesiveness of
pleomorphic cells. Among flat lesions, CISs exhibited more
pleomorphic and large cells compared with inflammatory
lesions as well as extensive acellular areas and indistinct
cell borders (Fig. 2).
Diagnostic Accuracy of pCLE
Our comparison of data from pCLE images and
histopathological reports is summarized in Table 2. The
data analysis revealed that the overall rate for diagnosis of
malignant to benign lesions with pCLE alone has a sensi-
tivity of 91.7% (95% confidence interval [CI], 84.2–96.3),
a specificity of 73.9% (95% CI 51.6–89.8), a PPV of 93.6%
(95% CI 88–96.7), and an NPV of 68.0% (95% CI
51.2–81.2). The overall sensitivity for the diagnosis of
high-grade versus low-grade papillary tumors was 94.5%
(95% CI 84.9–98.7). Its specificity was 66.7% (95% CI
41.0–86.7), the PPV was 89.7% (95% CI 81.8–94.4), and
FIG. 1 Pathology pictures and
probe-based confocal laser
endomicroscopy (pCLE) images
of the normal bladder (a-c) and
the resection bed after TUR-BT
(d, e). a Umbrella cells;
b intermediate cells; c lamina
propria; d fat tissue; and
e muscularis propria
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the NPV was 80.0% (95% CI 55.9–92.7). The overall
sensitivity for the diagnosis of CIS versus inflammation
was 71.4% (95% CI 47.8–88.7), the specificity was 81.3%
(95% CI 54.4–96.0), the PPV was 83.3% (95% CI
63.5–93.5), and the NPV was 68.4% (95% CI 51.4–81.6).
FIG. 2 Probe-based confocal
laser endomicroscopy (pCLE)
images. a, b Low-grade tumor
showing monomorphic cohesive
cells (dashed circle) with
distinct borders (dash line) and a
well-organized papillary
architecture. c, d High-grade
tumor displaying pleomorphic
noncohesive cells with
indistinct borders and
disorganized papillary
architecture (arrowheads). e,
f Inflammatory lesion showing
small monomorphic cells
(arrowheads) with small cells
arranged in clusters (dashed
circle) and loosely infiltrating
cells with distinct cell border in
the lamina propria (arrows). g,
h Carcinoma in situ presenting a
flat disorganized architecture
with pleomorphic and
noncohesive cells with an
indistinct border
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Therapeutic Effects of pCLE
In pCLE and non-pCLE groups, there were 28 and 16
lesions of T1 high-grade urothelial carcinoma, respec-
tively, which were analyzed to evaluate the therapeutic
effects of pCLE. The median follow-up time was 32.5
(interquartile range [IQR], 18.75–37.00) months. The
recurrence-free survival rate in 30 months was 78.2%
(95% CI 59.6–92.8) in the pCLE group and 60.3% (95% CI
40.0–90.9) in the non-pCLE group. The recurrence-free
survival was significantly longer in the pCLE group than in
the non-pCLE group (Fig. 3).
DISCUSSION
The standard procedure to diagnose and confirm bladder
cancer is TUR-BT performed under visualization with
conventional WLC. However, WLC has several well-rec-
ognized shortcomings. Due to its dependence on visual
appearance, WLC sometimes can overlook bladder cancer,
especially flat or subtle papillary lesions and CIS lesions
that appear as normal mucosa. This increases the chances
for an incomplete resection or positive surgical margins.
Jancke et al.13 reported that incomplete TUR-BT is a
common problem. Their study revealed that 26% of
patients had positive margins or residual tumors following
TUR-BT, which may be a risk factor for cancer recurrence.
Another limitation of WLC is that it is not useful in pre-
dicting specific tumor grades or invasion depth, factors that
influence the oncological outcomes of bladder cancer.
The limitations of conventional WLC have prompted the
development of a new generation of optical technologies,
such as NBI and BLC.14–17 Nevertheless, these technolo-
gies are limited to gross or macroscopic views and also
have demonstrated high false-positive detection rates.18,19
By contrast, pCLE offers real-time, in vivo histological
assessment, without the need for biopsies.20 In addition,
pCLE probes have a diverse range in sizes, from 0.9 to
2.5 mm, which can be fitted through the working channel
of both rigid and flexible cystoscopes.
Despite the potential usefulness of pCLE for bladder
cancer diagnosis, there is a lack of literature regarding its
efficacy. To our knowledge, until now only one study
reported the accuracy of pCLE in the diagnosis of bladder
cancer. Chang et al. evaluated the interobserver agreement
and diagnostic accuracy of pCLE for bladder cancer, and
they concluded that pCLE may have advantages compared
with WLC alone.21 However, compared with our study,
TABLE 2 Comparison of histological diagnosis versus pCLE diagnosis
Histopathological diagnosis pCLE diagnosis Total
Inflammation Papilloma Low malignant potential Low-grade tumor High-grade tumor CIS
Inflammation 13 0 0 0 0 3 16
Papilloma 0 4 0 0 0 0 4
Low malignant 0 0 0 3 0 0 3
potential
Low-grade 0 1 1 12 6 0 20
tumor
High-grade 0 0 0 3 52 0 55
tumor
CIS 6 0 0 0 0 15 21
Total 19 5 1 18 58 18 119
pCLE probe-based confocal laser endomicroscopy, CIS carcinoma in situ
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FIG. 3 Kaplan–Meier estimate between pCLE and non-pCLE
groups. Recurrence-free survival is significantly higher in the pCLE
group than in the non-pCLE group (p = 0.031)
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their study noted a relatively low specificity and sensitivity
for pCLE. Our study demonstrates high accuracy rates
between histological diagnosis and confocal images
regardless of tumor appearance and grade. These findings
are consistent with previous studies that have evaluated the
diagnostic role of pCLE in other organs.
In gastroenterology, Pohl et al.22 evaluated 296 biopsy
sites from 38 patients for high-grade dysplasia and early
carcinoma in Barrett’s esophagus patients to assess the
preliminary accuracy of pCLE. They report an overall
accuracy of 88% to 93%. Similarly, Dunbar et al. achieved
an accuracy of 97.8% for the diagnosis of chronic ulcera-
tive colitis with an integrated endoscope-based CLE
system.23
Recurrence and progression are more frequent in high-
grade bladder cancer.3–5 In our study, a sensitivity and a
PPV of 94.5% and 89.7%, respectively, were determined
for the pCLE-based differentiation between high-grade and
low-grade papillary tumors. Thus, pCLE is able to detect
high-grade cancers with high accuracy. When a high-grade
cancer was suspected, the operator had more evidence and
confidence to perform an adequately deep resection. This
change in the operative method may improve the onco-
logical outcome, and the bladder-preserving period can be
prolonged.
Our study also analyzed the therapeutic effect of pCLE
in T1 high-grade cancer. We found that within 30 months,
the recurrence-free rate was higher in patients who
underwent TUR-BT under pCLE than in the non-pCLE
group with 78.2% and 60.3%, respectively. The Kaplan–
Meier curve also shows a higher recurrence-free survival
rate for the pCLE group. Therefore, we conclude that
pCLE has therapeutic effects in addition to its diagnostic
purposes.
Additionally, pCLE was useful to differentiate flat
lesions, such as CIS and inflammation. It is known that CIS
has a high risk of tumor recurrence and progression. Failure
to identify CIS lesions may result in a worse prognosis.
Geavlete et al.24 reported that the CIS detection rate of
WLC is only 63%. In our study, however, the detection rate
of CIS by pCLE was 83.3%, which is almost 20% higher
than that by WLC alone. Therefore, pCLE may be a good
tool for an accurate diagnosis when CIS lesions hardly can
be distinguished clinically from a bladder inflammation.
There are many methods for enhancing the diagnostic
accuracy and therapeutic efficacy for bladder cancer. These
include fluorescence, BLC, NBI, molecular imaging, opti-
cal coherence tomography (OCT), and CLE. NBI and BLC
are used in clinical practice, but there are limitations to
what surgeons can discern from the relatively subjective
gross images. One of the most effective techniques to
distinguish abnormal lesions in real-time with high accu-
racy in the urological field seems to be pCLE. By providing
real-time histological images, it is a highly appropriate
procedure, which can be performed in the operating room.
Our study reveals that pCLE is one of the promising
methods that increase the detection rate of malignant
lesions, and the use of pCLE can aid in a more complete
resection of bladder cancer. It also may reduce the tumor
recurrence rate compared with TUR-BT done under con-
ventional WLC alone.
Despite the promising results reported in this study,
there are several limitations. First, although it is a
prospective study, there may be a bias, because pCLE and
non-pCLE groups are not completely randomized. Second,
to compare therapeutic effects of pCLE, only T1 high-
grade cases were selected, which have to be expanded to
other stages in the near future. Third, the operation was
performed by a single surgeon with an experience of a few
thousand TUR-BTs. Surgeons with less experience may
not reproduce our study results when they start performing
pCLEs. Fourth, the pCLE images were interpreted by a
single urology specialist; any inter-researcher variability
has not been considered in this setting. Fifth, the number of
lesions included in the study is small. Therefore, multi-
center studies with a larger cohort are needed.
CONCLUSIONS
Probe-based confocal laser endomicroscopy is a
promising method to detect malignant lesions of the blad-
der regardless of tumor appearance. It has a high accuracy
of differentiating CIS, low-, and high-grade urothelial
carcinomas with additional therapeutic efficacy by pro-
viding in real-time the surgeon with a tumor histology.
This has the potential to affect standard TUR-BTs and may
prompt the use of more appropriate procedures, thus
leading to longer recurrence-free periods.
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